honessan pharma
- Company typePrivate
- Founded-
- HeadquartersOakville, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
honessan pharma firmographics
Firmographics- Name
- honessan pharma
- Legal name
- Honessan Pharma Inc. / Pharma Honessan Inc.
- Website
- https://honessanpharma.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
honessan pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
- akta.pro secondary industries
- Full-Line Pharmaceutical Wholesalers (HLAIAJAA), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
Keywords
Where honessan pharma is headquartered
LocationHeadquarters
- HQ city
- Oakville
- HQ country
- Canada
- HQ region
- North America
Offices4 records
Markets served
honessan pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Infrastructure, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Specialty Pharmaceutical Products: Sale of specialty care prescription pharmaceutical products across therapeutic areas including Diabetes, Cardiovascular, Gastrointestinal, Nephrology, Immunosuppressants, and Hospital Line. Products are distributed through partners across Saudi Arabia and export markets.
- In-licensing and Distribution: Strategic in-licensing of specialty care products from global pharmaceutical partners for registration and commercialization in Saudi Arabia and GCC markets.
- Contract Manufacturing Services: Manufacturing capacity available for CDMO services, with approximately 350 million standard units annual capacity across multiple dosage forms for regional and global markets.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
honessan pharma product offering
Product offeringCore offering
Honessan Pharma develops, in-licenses, and distributes a portfolio of 20+ specialty pharmaceutical products across six therapeutic areas (Gastrointestinal, Diabetes, Cardiovascular, Nephrology, Immunosuppressants, Hospital Line), anchored by Gitodux (Vonoprazan), the first potassium-competitive acid blocker (PCAB) registered in Saudi Arabia. The company is building a 32,000 m² GMP-compliant manufacturing facility in Al Madinah Al Munawwarah (commissioning Q4 2027) with ~350 million standard units annual capacity spanning oral solids, semi-solids/topicals, and sterile injectables, and offers CDMO capacity, technology transfer, and licensing partnerships for the Saudi Arabia and GCC markets.
Product overview
Honessan Pharma operates as a specialty pharmaceutical company with a portfolio of 20+ specialty care products spanning six therapeutic areas: Gastrointestinal, Diabetes, Cardiovascular, Nephrology, Immunosuppressants, and Hospital Line. The company's flagship product is Gitodux (Vonoprazan), the first PCAB approved in Saudi Arabia. Honessan Pharma provides end-to-end pharmaceutical solutions encompassing advanced R&D, world-class GMP manufacturing, and strategic product distribution. The manufacturing facility in Al-Madinah Al-Monawara produces oral solids, semi-solids, and injectables with an annual capacity of approximately 350 million standard units.
Differentiator
Problem solved
Functional benefit
Brands
- Gitodux: Flagship product - Vonoprazan, the first potassium-competitive acid blocker (PCAB) in Saudi Arabia for acid-related disorders.
Products and services
- Gitodux (Vonoprazan) Flagship specialty pharmaceutical product of Honessan Pharma; the first potassium-competitive acid blocker (PCAB) registered in Saudi Arabia, offering next-generation therapy for acid-related disorders with superior and consistent acid suppression compared to traditional PPIs. Targeted at gastroenterology prescribers and patients with acid-related gastrointestinal conditions in Saudi Arabia.
- Sitagliptin (Diabetes Portfolio) Registered specialty pharmaceutical product for diabetes treatment, expanding Honessan Pharma's Diabetes therapeutic area portfolio in Saudi Arabia. Targeted at endocrinologists, diabetologists, and patients requiring diabetes therapy.
- Pharmaceutical Contract Manufacturing (CDMO) Services Planned contract manufacturing / CDMO capacity from Honessan Pharma's 32,000 m² GMP-compliant manufacturing facility in Al Madinah Al Munawwarah, producing oral solid dosage forms (tablets, capsules, film-coated products), semisolid and topical products (creams, ointments, gels), and sterile injectables (vials, ampoules, parenteral preparations). Targeted at global and regional pharmaceutical companies seeking GMP manufacturing capacity in the Middle East.
- Specialty Pharmaceutical In-Licensing & Distribution Partnerships Strategic in-licensing and partnership program through which Honessan Pharma registers, commercializes, and distributes specialty pharmaceutical products from global partners (e.g., Batavia Biosciences, Seacross, Invent Farma, Combino Pharm, aRDi Farma, Razi Al-Madina, Ekuberg Pharma) across Saudi Arabia, GCC, Iraq, and Africa, supported by the Al-Naghi distribution agreement for Saudi Arabia. Targeted at global pharmaceutical companies seeking Middle East/GCC market entry.
Quantifiable outcome
- First PCAB (potassium-competitive acid blocker) approved in Saudi Arabia - Gitodux (Vonoprazan)
- +3 more outcomes
Companies that use honessan pharma
Customer profileSegments3 records
Ideal customer profiles2 records
honessan pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature2 records
honessan pharma partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Al-NaghicoreDistribution agreement signed in 2024 for distribution of pharmaceutical products across Saudi Arabia. Al-Naghi is a trusted healthcare and pharmaceutical distribution partner in Saudi Arabia.
- Batavia BiosciencesminorGlobal pharmaceutical partner specializing in vaccine and biopharmaceutical development. Part of Honessan's network of pharmaceutical partnerships for innovative product development.
- PSI CROminorContract research organization providing clinical development services. Partner in Honessan's collaborative approach spanning the pharmaceutical value chain.
- Ekuberg PharmaminorPharmaceutical development partner contributing to Honessan's product portfolio and technology capabilities.
- Invent FarmaminorPharmaceutical partner providing specialty products and manufacturing capabilities for the Saudi and GCC markets.
- Combino PharmminorPharmaceutical company specializing in sterile and specialty products. Strategic partner in Honessan's product supply network.
- Seacross PharmaceuticalsminorGlobal pharmaceutical partner contributing specialty products to Honessan's portfolio for Saudi market registration.
- GüteMedminorPharmaceutical quality and compliance partner in Honessan's network.
- aRDi FarmaminorRegional pharmaceutical partner providing specialty products for the Middle East market.
- Razi Al-Madina PharmaceuticalminorRegional pharmaceutical manufacturer and partner in the Saudi pharmaceutical ecosystem.
Scale indicators8 records
Recent moves7 records
Expansion highlights4 records
honessan pharma competitors and assessment
Company assessmentDirect peers
- Tabuk Pharmaceuticals: One of the largest Saudi pharmaceutical manufacturers producing branded generics and specialty products. Directly comparable as a Saudi-based pharma manufacturer with a multi-therapeutic portfolio and Vision 2030 alignment.
- Hikma Pharmaceuticals: MENA-focused specialty and generic pharmaceutical company with branded, injectable, and manufacturing operations. Comparable for specialty pharma positioning across the Middle East and adjacent distribution model.
- Saudi Drug Store Company (SDSC): Leading pharmaceutical distributor in Saudi Arabia. Directly comparable to Honessan's distribution channel function and represents an alternative route to market for KSA-launched specialty pharma products.
- SPIMACO Addwaeih: Saudi Pharmaceutical Industries & Medical Appliances Corporation — major Saudi pharma manufacturer with branded generics, specialty products, and CDMO capabilities. Closest direct comp for local manufacturing + specialty distribution in KSA.
Regional players
- Pharco Pharmaceuticals: Egypt-based pharmaceutical manufacturer with multi-therapeutic portfolio and regional MENA distribution. Comparable regional specialty pharma manufacturer with similar market positioning across the Middle East.
- Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with manufacturing across multiple dosage forms and MENA distribution. Regional peer operating similar specialty pharma + manufacturing model but with broader geographic footprint.
Broad incumbents
- Aurobindo Pharma: Global generic and specialty pharmaceutical manufacturer with CDMO/CMO services and large-scale API/finished dose capacity. Comparable for the planned CDMO revenue stream and integrated manufacturing platform.
- Cipla: Global pharmaceutical manufacturer with strong specialty portfolio across respiratory, cardiovascular, and other chronic segments; comparable for therapeutic area overlap and emerging-market distribution strategy.
- Dr. Reddy's Laboratories: Global integrated pharmaceutical company with significant CDMO services, specialty portfolio, and emerging market operations. Comparable for planned CDMO services and specialty pharmaceutical business model.
Emerging players
- Aspen Pharmacare: Specialty pharma manufacturer with strong presence in emerging markets and manufacturing in multiple regions. Comparable for specialty pharma focus and emerging-market distribution strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
honessan pharma social profiles
Digital presencehonessan pharma compliance and trust
Trust signalCompliance1 record
honessan pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
honessan pharma leadership team
Management profileNumber of profiles
honessan pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
honessan pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about honessan pharma
What does honessan pharma do?
Honessan Pharma develops, in-licenses, and distributes a portfolio of 20+ specialty pharmaceutical products across six therapeutic areas (Gastrointestinal, Diabetes, Cardiovascular, Nephrology, Immunosuppressants, Hospital Line), anchored by Gitodux (Vonoprazan), the first potassium-competitive acid blocker (PCAB) registered in Saudi Arabia. The company is building a 32,000 m² GMP-compliant manufacturing facility in Al Madinah Al Munawwarah (commissioning Q4 2027) with ~350 million standard units annual capacity spanning oral solids, semi-solids/topicals, and sterile injectables, and offers CDMO capacity, technology transfer, and licensing partnerships for the Saudi Arabia and GCC markets.
Is honessan pharma a public or private company?
honessan pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was honessan pharma founded?
honessan pharma was founded in -1. It employs 1 to 10 people.
Where is honessan pharma based?
honessan pharma is headquartered in Oakville, Canada, in the North America region.
How does honessan pharma make money?
Three revenue lines are on record. Specialty Pharmaceutical Products are the primary driver. The others are in-licensing and Distribution and contract Manufacturing Services.
Who are honessan pharma's main competitors?
Direct peers on record are Tabuk Pharmaceuticals, Hikma Pharmaceuticals, Saudi Drug Store Company (SDSC) and SPIMACO Addwaeih. Regional players are Pharco Pharmaceuticals and Julphar (Gulf Pharmaceutical Industries). Broad incumbents are Aurobindo Pharma, Cipla and Dr. Reddy's Laboratories. Aspen Pharmacare is listed as an emerging player.
Does honessan pharma have an API?
No public API is recorded for honessan pharma.
What industry is honessan pharma in?
honessan pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAIAJAA, Full-Line Pharmaceutical Wholesalers. Its NAICS code is 325412 and its SIC code is 2834.